Retransfusion or Not of Cardiotomy Blood

Not Applicable

• Conditions: Blood Loss, Surgical

• Registration Number: NCT04574128
• Lead Sponsor: Örebro University, Sweden

Brief Summary

This randomised controlled trial has a non-inferiority design. The aim is to test if the blood loss (volume in mL and hemoglobin) is effected by heart and lung cardiotomy retransfusion, or not? Forty CABG (Coronary Artery By pass Grafting) patients will be allocated to either receive retransfusion (n=20) of cardiotomy blood via the heart and lung mashine, or no retransfusion (n=20).

Detailed Description

Not available

Study Timeline

• Status Verified: 2020-09
• Study First Submitted: 2020-09-21
• Study First Submitted QC: 2020-09-28
• Last Update Submitted: 2020-09-28
• Study Start: 2020-10-01
• Study First Posted: 2020-10-05
• Last Update Posted: 2020-10-05
• Primary Completion: 2021-08-30
• Study Completion: 2022-12-30

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

• Elective CABG.

Exclusion Criteria

• Anaemia, infection, massive bleeding, CABG off pump.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SEQUENTIAL

Primary Outcome Measures

Name	Time	Method
blood loss	During 5 days hemoglobin will be measured as the clinical rutine or as needed.	Hemoglobin
Blood loss	During 2 days or while surgical drains remains, blood volume in mL is measured.	Blood volume in millilitre (mL)

Trial Locations

Locations (1)

University Hospital in Örebro; 🇸🇪 Örebro, Sweden